Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
F. Hoffmann-La Roche Ltd In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions…